ArticleAntimicrobial agents and chemotherapy2014
Caspofungin at catheter lock concentrations eradicates mature biofilms of Candida lusitaniae and Candida guilliermondii.
Article in Antimicrobial agents and chemotherapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 20 citations in OpenAlex.
- Antibiofilm activity of manogepix, ibrexafungerp, amphotericin B, rezafungin, and caspofungin againstAntimicrobial agents and chemotherapy · 2025Article
- Article
- Three Successfully Treated Cases ofMicroorganisms · 2023Article
- Biofilm: The invisible culprit in catheter-induced candidemia.AIMS microbiology · 2023Review
- Antifungal lock therapy: an eternal promise or an effective alternative therapeutic approach?Letters in applied microbiology · 2022Review
- Review
- Article
- DisseminatedCase reports in infectious diseases · 2021Article
- Novel and potent antimicrobial effects of caspofungin on drug-resistant Candida and bacteria.Scientific reports · 2020Article
- What Could Be the Role of Antifungal Lock-Solutions? From Bench to Bedside.Pathogens (Basel, Switzerland) · 2018Review
- Evaluation of the antileishmanial potency, toxicity and phytochemical constituents of methanol bark extract of Sterculia villosa.Pharmaceutical biology · 2017Article
- Successful therapy of Candida pulcherrima fungemia in a premature newborn with liposomal amphotericin B and micafungin.Medical mycology case reports · 2016Article
- Growth Inhibition and Membrane Permeabilization of Candida lusitaniae Using Varied Pulse Shape Electroporation.BioMed research international · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The antibiofilm activities of caspofungin, anidulafungin, micafungin, and liposomal amphotericin B were studied against Candida lusitaniae, Candida guilliermondii, and a Candida albicans control strain. While anidulafungin and micafungin (0.007 to 2,048 mg/liter) showed reduced activity against biofilms of both test species, caspofungin displayed concentration-dependent antibiofilm activity, reaching complete and persistent eradication at concentrations achievable during lock therapy (512 to 2,048 mg/liter, P < 0.05). Although liposomal amphotericin B strongly inhibited mature biofilms, it possessed lower antibiofilm activity than caspofungin (P < 0.05).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.